The SVIN-Trial-Just Another Brick in the Wall?
作者信息
Mehtani Rohit
机构信息
Department of Hepatology, Amrita Institute of Medical Sciences and Research Centre, Faridabad, Haryana, India.
出版信息
J Clin Exp Hepatol. 2025 Mar-Apr;15(2):102449. doi: 10.1016/j.jceh.2024.102449. Epub 2024 Oct 30.
Abstract
摘要
相似文献
1
The SVIN-Trial-Just Another Brick in the Wall?SVIN试验——只是墙上的又一块砖？
J Clin Exp Hepatol. 2025 Mar-Apr;15(2):102449. doi: 10.1016/j.jceh.2024.102449. Epub 2024 Oct 30.
2
Is cognitive motor dissociation just a minimally conscious state "plus" by another name?认知运动分离是否只是换了个名字的轻微意识状态“加”？
medRxiv. 2025 Jun 18:2025.06.11.25329346. doi: 10.1101/2025.06.11.25329346.
3
Emerging adults' neuroticism links with depressive symptoms through personal belief in a just world and forgiveness.新兴成年人的神经质通过对公正世界的个人信念和宽恕与抑郁症状相关联。
Front Psychol. 2025 Jun 18;16:1489371. doi: 10.3389/fpsyg.2025.1489371. eCollection 2025.
4
Human exposure to pollutant emissions from brick kilns and their association with ocular health and neurotoxic symptoms: a pilot study in the Refugio Brickmaking Area, León, Mexico.人类接触砖窑污染物排放及其与眼部健康和神经毒性症状的关联：墨西哥莱昂雷富希奥制砖区的一项试点研究。
Front Psychiatry. 2025 Jun 13;16:1554101. doi: 10.3389/fpsyt.2025.1554101. eCollection 2025.
5
Patient-controlled analgesia with remifentanil versus alternative parenteral methods for pain management in labour.瑞芬太尼患者自控镇痛与其他胃肠外方法用于分娩疼痛管理的比较
Cochrane Database Syst Rev. 2017 Apr 13;4(4):CD011989. doi: 10.1002/14651858.CD011989.pub2.
6
Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine-device use.预防或治疗宫内节育器使用相关的月经过多或疼痛的干预措施。
Cochrane Database Syst Rev. 2022 Aug 26;8(8):CD006034. doi: 10.1002/14651858.CD006034.pub3.
7
Therapeutic ultrasound for carpal tunnel syndrome.用于腕管综合征的治疗性超声
Cochrane Database Syst Rev. 2012 Jan 18;1:CD009601. doi: 10.1002/14651858.CD009601.
8
Implementing Just Culture to Improve Patient Safety.实施公正文化以提高患者安全。
Mil Med. 2022 May 18. doi: 10.1093/milmed/usac115.
9
A Brief Engagement Intervention Adapted for Racial and Ethnic Minority Young Adults in Mental Health Services: Protocol for a Pilot Optimization Trial.一种为心理健康服务中的少数族裔年轻人改编的简短参与干预措施：一项试点优化试验方案
JMIR Res Protoc. 2025 Jun 17;14:e68885. doi: 10.2196/68885.
10
Bladder training for urinary incontinence in adults.成人尿失禁的膀胱训练
Cochrane Database Syst Rev. 2004;2004(1):CD001308. doi: 10.1002/14651858.CD001308.pub2.
本文引用的文献
1
A Prospective Randomised Comparative Four-arm Intervention Study of Efficacy and Safety of Saroglitazar and Vitamin E in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH)-SVIN TRIAL.一项关于沙罗格列他与维生素E治疗非酒精性脂肪性肝病（NAFLD）/非酒精性脂肪性肝炎（NASH）疗效和安全性的前瞻性随机对照四臂干预研究——SVIN试验
J Clin Exp Hepatol. 2024 Sep-Oct;14(5):101398. doi: 10.1016/j.jceh.2024.101398. Epub 2024 Mar 18.
2
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.一项评估 Resmetirom 治疗伴有肝纤维化的 NASH 的 3 期随机对照试验。
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
3
Efficacy and safety of saroglitazar in real-world patients of non-alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience.沙罗格列扎在合并或不合并糖尿病（包括代偿期肝硬化）的非酒精性脂肪性肝病真实世界患者中的疗效和安全性：一家三级医疗中心的经验
JGH Open. 2023 Feb 20;7(3):215-220. doi: 10.1002/jgh3.12878. eCollection 2023 Mar.
4
Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD).印度国家肝脏研究协会（INASL）关于非酒精性脂肪性肝病（NAFLD）命名、诊断和治疗的指导文件。
J Clin Exp Hepatol. 2023 Mar-Apr;13(2):273-302. doi: 10.1016/j.jceh.2022.11.014. Epub 2022 Dec 7.
5
Saroglitazar for Nonalcoholic Fatty Liver Disease: A Single Centre Experience in 91 Patients.司美格鲁肽治疗非酒精性脂肪性肝病：91例患者的单中心经验
J Clin Exp Hepatol. 2022 Mar-Apr;12(2):435-439. doi: 10.1016/j.jceh.2021.06.015. Epub 2021 Jun 19.
6
Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study.沙罗格列扎用于合并糖尿病血脂异常的非酒精性脂肪肝患者的安全性和有效性——一项前瞻性、干预性、试点研究
J Clin Exp Hepatol. 2022 Jan-Feb;12(1):61-67. doi: 10.1016/j.jceh.2021.03.012. Epub 2021 Apr 9.
7
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.沙格列汀，一种 PPAR-α/γ 激动剂，用于治疗非酒精性脂肪性肝病：一项随机对照、双盲 2 期试验。
Hepatology. 2021 Oct;74(4):1809-1824. doi: 10.1002/hep.31843. Epub 2021 Jul 19.
8
Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study.非酒精性脂肪性肝病合并糖尿病血脂异常患者应用沙格列汀：一项前瞻性、观察性、真实世界研究。
Sci Rep. 2020 Dec 3;10(1):21117. doi: 10.1038/s41598-020-78342-x.
9
A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis.一项沙格列汀治疗非酒精性脂肪性肝炎患者的 2 期双盲、随机对照临床试验。
Clin Gastroenterol Hepatol. 2021 Dec;19(12):2670-2672. doi: 10.1016/j.cgh.2020.10.051. Epub 2020 Nov 2.
10
An Observational Study of Reduction in Glycemic Parameters and Liver Stiffness by Saroglitazar 4 mg in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.一项关于4毫克沙罗格列扎对2型糖尿病合并非酒精性脂肪性肝病患者血糖参数及肝脏硬度降低作用的观察性研究。
Cureus. 2020 Jul 8;12(7):e9065. doi: 10.7759/cureus.9065.
Zotero 插件